UnitedHealth Group surpassed analyst expectations, prompting the company to raise its annual earnings forecast and reinforcing investor confidence in its broader financial recovery. Abbott Laboratories mirrored this momentum, reporting increased second-quarter revenue driven primarily by the strong performance of its diagnostics division.

Eli Lilly expanded its footprint in the mental health space by agreeing to acquire AtaiBeckley for $2.8 billion. The all-cash deal, valued at $6.75 per share, represents a 26% premium over the biopharmaceutical firm’s previous closing price. Simultaneously, Merck secured a critical regulatory win as the FDA approved Lipfendra, a first-of-its-kind treatment designed to reduce cholesterol levels beyond the efficacy of traditional statin therapy.